Molecular signature-assisted drug selection may improve results in rheumatoid arthritis

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy.
“This study reports the second interim analysis of the [Accelerate Information of Molecular Signatures (AIMS)] real-world study evaluating the clinical utility of the [molecular signature response classifier (MSRC)] test,” Vibeke Strand, MD, adjunct clinical professor at the division of immunology and rheumatology at the Stanford University School of

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy.
“This study reports the second interim analysis of the [Accelerate Information of Molecular Signatures (AIMS)] real-world study evaluating the clinical utility of the [molecular signature response classifier (MSRC)] test,” Vibeke Strand, MD, adjunct clinical professor at the division of immunology and rheumatology at the Stanford University School of